Charges in Alleged Scheme
The FDA reports federal charges against two Indian nationals in an alleged counterfeit Ozempic distribution scheme.
Alleged Source
The charges name Swapnadip Roy and Vicky Ramancha; court documents allege they obtained counterfeit Ozempic from unauthorized sources in China.
Alleged Sales
The indictment alleges sales at deeply discounted prices to U.S. distributors during July 2023 through April 2024.
Counterfeit Components
The FDA said products allegedly had counterfeit packaging, package inserts, pen labels, and needles intended to appear manufacturer-authorized.
Intended Customers
The alleged scheme was intended to deceive pharmacies and patients downstream, according to the FDA announcement.
Charges Are Allegations
The FDA emphasizes an indictment is only an allegation; defendants are presumed innocent until proven guilty beyond a reasonable doubt in court.
Reporting Concerns
The FDA says suspected counterfeit products and sellers can be reported through its reporting resource linked in the official notice.
Read the FDA Notice
Read the FDA’s official notice for the precise allegations, reporting link, and consumer contact information.